145 related articles for article (PubMed ID: 38362771)
1. Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status?
Ma SS; Wang RR; Peng Q; Liu Y; Qian JY; Li MJ; Li K; Huang ZY; Wu LL; Xie D
Thorac Cancer; 2024 Mar; 15(9):715-721. PubMed ID: 38362771
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma.
Yang F; Sun K; Li F; Li X; Shi J; Sun X; Hong Y; Jiang G; Zhu Y; Song X
Ann Thorac Surg; 2024 Jun; 117(6):1111-1119. PubMed ID: 37353101
[TBL] [Abstract][Full Text] [Related]
4. The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
Xie M; Gao J; Ma X; Song J; Wu C; Zhou Y; Jiang T; Liang Y; Yang C; Bao X; Zhang X; Yao J; Jing Y; Wu J; Wang J; Xue X
BMC Cancer; 2024 Mar; 24(1):372. PubMed ID: 38528507
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.
Ambrosini-Spaltro A; Rengucci C; Capelli L; Chiadini E; Calistri D; Bennati C; Cravero P; Limarzi F; Nosseir S; Panzacchi R; Valli M; Ulivi P; Rossi G
Curr Oncol; 2023 Nov; 30(11):10019-10032. PubMed ID: 37999148
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma.
Li Z; Jiang L; Bai H; Wang Z; Zhao J; Duan J; Yang X; An T; Wang J
Thorac Cancer; 2015 May; 6(3):269-74. PubMed ID: 26273372
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
9.
Da R; Wang M; Jiang H; Wang T; Wang W
Front Oncol; 2020; 10():531968. PubMed ID: 33489866
[TBL] [Abstract][Full Text] [Related]
10. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
11. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.
Taieb J; Zaanan A; Le Malicot K; Julié C; Blons H; Mineur L; Bennouna J; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Lepage C; Emile JF; Laurent-Puig P
JAMA Oncol; 2016 May; 2(5):643-653. PubMed ID: 26768652
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population.
Ye Z; Xia X; Xu P; Liu W; Wang S; Fan Y; Guo M
Int J Endocrinol; 2022; 2022():6562149. PubMed ID: 35755312
[TBL] [Abstract][Full Text] [Related]
17. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.
Gu Z; Huang P; Zhao J; Luo C; Liao L; Liu A; Huang L
Int J Cancer; 2024 Jun; 154(11):1979-1986. PubMed ID: 38353428
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma.
Zheng D; Wang R; Pan Y; Zheng S; Zhang Y; Li H; Cheng C; Gong R; Li Y; Shen X; Hu H; Cai D; Cheng X; Sun Y; Chen H
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1284-91. PubMed ID: 26202550
[TBL] [Abstract][Full Text] [Related]
20. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
